A pharmacogenetic strategy for immunosuppression based on the CYP3A5 genotype

被引：50

作者：

MacPhee, Iain A. M. ^{[1
]}

Holt, David W. ^{[1
]}

机构：

[1] Univ London, London SW17 0RE, England

来源：

TRANSPLANTATION | 2008年 / 85卷 / 02期

关键词：

pharmacogenetics; immunosuppression; tacrolimus; CYP3A5; transplantation;

D O I：

10.1097/TP.0b013e3181609054

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Pharmacogenetics has the potential to complement therapeutic drug monitoring in achieving target blood concentrations of the immunosuppressive drugs during the critical early period after transplantation when adequate drug exposure is essential to prevent rejection. The most attractive candidate for a pharmacogenetic strategy is tacrolimus dosing based on the CYP3A5 genotype.

引用

收藏

页码：163 / 165

页数：3

相关论文

共 14 条

[1] Consequences of genetic polymorphisms for sirolimus requirements after renal transplant in patients on primary sirolimus therapy [J].

Anglicheau, D ;

Le Corre, D ;

Lechaton, S ;

Laurent-Puig, P ;

Kreis, H ;

Beaune, P ;

Legendre, C ;

Thervet, E .

AMERICAN JOURNAL OF TRANSPLANTATION, 2005, 5 (03) :595-603

[2] Induction of multidrug resistance-1 and cytochrome P450 mRNAs in human mononuclear cells by rifampin [J].

Asghar, A ;

Gorski, JC ;

Haehner-Daniels, B ;

Hall, SD .

DRUG METABOLISM AND DISPOSITION, 2002, 30 (01) :20-26

[3] Adequate early cyclosporin exposure is critical to prevent renal allograft rejection: Patients monitored by absorption profiling [J].

Clase, CM ;

Mahalati, K ;

Kiberd, BA ;

Lawen, JG ;

West, KA ;

Fraser, AD ;

Belitsky, P .

AMERICAN JOURNAL OF TRANSPLANTATION, 2002, 2 (08) :789-795

[4] Genotyping cytochrome P450 3A5 using the light cycler [J].

Fredericks, S ;

Moreton, M ;

MacPhee, IAM ;

Mohamed, M ;

Marlowe, S ;

Jorga, AM ;

Johnston, A ;

Carter, ND ;

Holt, DW .

ANNALS OF CLINICAL BIOCHEMISTRY, 2005, 42 :376-381

[5] Multi-drug resistance gene-1 (MDR-1) haplotypes and the CYP3A5*1 genotype have no influence on ciclosporin dose requirements as assessed by C0 or C2 measurements [J].

Fredericks, Salim ;

Jorga, AnaMaria ;

MacPhee, Iain A. M. ;

Reboux, Sandrine ;

Shiferaw, Elizabeth ;

Moreton, Michelle ;

Carter, Nicholas D. ;

Holt, David W. ;

Johnston, Atholl .

CLINICAL TRANSPLANTATION, 2007, 21 (02) :252-257

[6] The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients [J].

Haufroid, V ;

Mourad, M ;

Van Kerckhove, V ;

Wawrzyniak, J ;

De Meyer, M ;

Eddour, DC ;

Malaise, J ;

Lison, D ;

Squifflet, JP ;

Wallemacq, P .

PHARMACOGENETICS, 2004, 14 (03) :147-154

[7] Effects of genetic polymorphisms of CYP3A4, CYP3A5 and MDR1 on cyclosporine pharmacokinetics after renal transplantation [J].

Hu, Yong-Fang ;

Qiu, Wen ;

Liu, Zhao-Qian ;

Zhu, Li-Jun ;

Liu, Zhong-Qi ;

Tu, Jiang-Hua ;

Wang, Dan ;

Li, Zhi ;

He, Jun ;

Zhong, Gan-Ping ;

Zhou, Gan ;

Zhou, Hong-Hao .

CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2006, 33 (11) :1093-1098

[8] Pharmacogenetics as a tool for optimising drug therapy in solid-organ transplantation [J].

Liang, Fu N. G. ;

Holt, David W. ;

MacPhee, Iain A. M. .

EXPERT OPINION ON PHARMACOTHERAPY, 2007, 8 (13) :2045-2058

[9] The influence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation [J].

MacPhee, IAM ;

Fredericks, S ;

Tai, T ;

Syrris, P ;

Carter, ND ;

Johnston, A ;

Goldberg, L ;

Holt, DW .

AMERICAN JOURNAL OF TRANSPLANTATION, 2004, 4 (06) :914-919

[10] Tacrolimus pharmacogenetics: The CYP3A5*1 allele predicts low dose-normalized tacrolimus blood concentrations in whites and south Asians [J].

MacPhee, IAM ;

Fredericks, S ;

Mohamed, M ;

Moreton, M ;

Carter, ND ;

Johnston, A ;

Goldberg, L ;

Holt, DW .

TRANSPLANTATION, 2005, 79 (04) :499-502